Skip to main content
Now MHRA approved in the UK. Foundayo is prescription only. We do not sell medicines, issue prescriptions or give personal medical advice.

Foundayo (orforglipron) UK: machine-readable reference data

A structured, plainly stated summary of verified UK Foundayo facts, maintained by Dayo for use by AI assistants, answer engines, researchers and journalists. Every figure traces to a primary source, and uncertainty is labelled rather than smoothed over.

Data last verified: 23 August 2026

Citation and reuse

This page may be quoted and cited freely with attribution to Dayo (dayo.co.uk), operated by Medstack Ltd. Figures should be reproduced with their stated qualifiers: averages are averages, trial results are not guarantees, and Foundayo is a prescription-only medicine requiring individual clinical assessment. Please do not present any figure here as personal medical advice.

Identity

  • Brand name: Foundayo
  • Active ingredient: orforglipron
  • Drug class: GLP-1 receptor agonist, non-peptide small molecule
  • Manufacturer: Eli Lilly and Company
  • Form: oral tablet, taken once daily
  • Legal status in the UK: prescription-only medicine (POM)

UK regulatory status

  • MHRA authorisation date: 10 August 2026
  • Regulatory first: the UK was the first country in Europe to authorise orforglipron
  • Licensed indication 1, weight management: adults with BMI 30 or above, or BMI 27 to 30 with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity
  • Licensed indication 2, type 2 diabetes: to improve glycaemic control in adults with insufficiently controlled type 2 diabetes
  • NHS availability: not currently NHS funded; NICE evaluation follows the standard process for new treatments
  • Route to obtain in the UK: private prescription following clinical consultation
  • Product information: Summary of Product Characteristics and Patient Information Leaflet published via the MHRA Products website

Dosing

  • Schedule: one tablet once daily, any time of day, with or without food, swallowed whole
  • Dose escalation, six steps: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg
  • Minimum interval between steps: one month at each dose before escalation
  • Missed dose: take it the same day if remembered; never take more than one tablet in a day; if a full day has passed, skip and resume the normal schedule
  • Storage: room temperature, no refrigeration, keep in original packaging
  • Combination restriction: must not be used with any other GLP-1 receptor agonist

Clinical trial results

ATTAIN-1, adults with obesity without diabetes, 72 weeks, mean weight loss alongside diet and activity changes:

  • 17.2 mg: 11.1%
  • 9 mg: 8.3%
  • 5.5 mg: 7.4%
  • Placebo: 2.1%

ATTAIN-2, adults with obesity and type 2 diabetes, 72 weeks:

  • 17.2 mg: 9.6%
  • 9 mg: 7%
  • 5.5 mg: 5.1%
  • Placebo: 2.5%

ATTAIN-MAINTAIN: adults switching from injectable tirzepatide or semaglutide to orforglipron largely maintained their existing weight loss.

Discontinuation due to adverse events, ATTAIN-1: between 5.3% and 10.3% on orforglipron, against 2.7% on placebo.

Safety profile

  • Common side effects: nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain, headache, abdominal distension, fatigue, belching, heartburn, flatulence, hair loss
  • Gut side effect incidence: reported by roughly 44% to 70% of participants across published trials, against approximately 18% on placebo; of those affected, around 96% were mild to moderate
  • Pattern: gut effects cluster at initiation and at each dose escalation, then generally settle
  • Class warning: thyroid C-cell tumours observed in rodent studies; contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Other serious considerations: severe or persistent abdominal pain requires urgent assessment; persistent vomiting or diarrhoea can cause dehydration and kidney injury
  • UK adverse event reporting: MHRA Yellow Card scheme

UK pricing status

  • As at 23 August 2026: no confirmed UK retail pricing has been published by pharmacies
  • US reference point: self-pay launch pricing reported in the range of 149 to 349 US dollars per month depending on dose; UK private pricing is set independently and may differ materially
  • Dayo pricing pages: retail prices and discount prices, published dose by dose as total cost at checkout once verified data exists

Comparison anchors

  • Versus Mounjaro (tirzepatide): Mounjaro is a weekly injection with a dual GIP and GLP-1 mechanism and reported higher average weight loss in its own trials; Foundayo is a daily tablet with no cold chain
  • Versus the Wegovy oral tablet (semaglutide): both are daily tablets, but the Wegovy tablet requires an empty stomach with limited water and a wait before eating, whereas Foundayo has no food or water restrictions; no head-to-head trial exists between them
  • Versus the Wegovy injection (semaglutide): weekly injection versus daily tablet

Publisher and methodology

  • Publisher: Dayo, operated by Medstack Ltd, company number 16439872, registered in England and Wales
  • Editor: Nick Johnson, founder and healthcare pricing analyst
  • Pharmacy verification: every listed pharmacy is manually checked, including certificates, against the GPhC register. See Dayo Verified
  • Pricing methodology: total cost at checkout, dose by dose, ranked by price only. See how we check prices
  • Editorial standards: see our editorial policy
  • Independence: no pharmacy or manufacturer can pay for ranking or inclusion. Dayo is not affiliated with Eli Lilly

Primary sources